Pre-Stroke Long-Term Fasting Blood Glucose Level and Glucose Variability with Post-Stroke All-Cause Mortality in Nondiabetic Ischemic Stroke Patients from Northwestern China
Related Experiment Video
Updated: May 7, 2026

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients
Published on: March 11, 2021
Huiwen Gu1, Kuiying Gu1, Qi Huang2
1School of Public Health, Soochow University, Suzhou, China.
Introduction:
The influence of pre-stroke long-term fasting blood glucose (FBG) and its variability on post-stroke all-cause mortality in ischemic stroke (IS) patients without diabetes remains unclear. This study aimed to investigate their independent and joint effects on all-cause mortality in this specific population.
Methods:
We included 193,705 nondiabetic IS patients from the Northwest China Real-world and Population-based Tianshan Cohort 2019-2023. Cox proportional hazards regression models assessed the associations of impaired fasting glucose (IFG; 6.1-6.9 mmol/L) and high FBG variability with post-stroke all-cause mortality risk. Additive and multiplicative interactions between the two exposures were evaluated using the delta method and likelihood ratio tests, respectively.
Results:
Overall, 14,481 patients (7.5%) died during a median follow-up of 0.87 years. IFG showed no significant association with mortality risk. Higher FBG variability (logVIM Q5 vs. Q1) significantly raised mortality risk (HR 1.56, 95% CI: 1.48-1.64; p trend < 0.001). A significant interaction between IFG and high FBG variability was observed on both additive (RERI 0.30, 95% CI: 0.13-0.49; p = 0.006) and multiplicative scales (HR 1.34, 95% CI: 1.13-1.58; p = 0.001).
Conclusions:
Long-term pre-stroke FBG variability is an independent predictor of post-stroke all-cause mortality among nondiabetic IS patients, while IFG is not. However, IFG amplifies the effect of FBG variability. Their combination shows synergistic risk elevation.
More Related Videos
Related Concept Videos
Diabetes: Symptoms, Diagnosis, and Complications
Hypoglycemia and Glucagon
Heart Failure VI: Adjunct Therapies
Hypoglycemia
Hyperglycemia
Diabetic Nephropathy

